BMO Capital Markets upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from an underperform rating to a market perform rating in a research report sent to investors on Thursday, Marketbeat reports. They currently have $96.00 target price on the stock, up from their previous target price of $91.00. NBIX has been the subject of […]
BMO Capital Markets upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from an underperform rating to a market perform rating in a research note published on Thursday, Marketbeat.com reports. BMO Capital Markets currently has $96.00 price target on the stock, up from their previous price target of $91.00. A number of other equities research […]
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the seventeen brokerages that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month […]
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month price […]
Artia Global Partners LP purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,000 shares of the company’s stock, valued at approximately $5,375,000. Neurocrine Biosciences accounts for approximately […]